Tuberculosis (TB) is a major global public health problem in which one in four of the world’s population is latently infected. Host-directed therapeutics, in which drugs target host-mediated responses to pathogens rather than acting directly on the pathogen, are an emerging and promising strategy. In order to develop this approach towards new drugs for TB, we urgently require a comprehensive understanding of how host-pathogen interactions impact cellular pathways to regulate the immune response to the pathogen and influence disease outcome.
Metabolic reprogramming is crucial for determining successful immune responses. It is now well known that infection with Mycobacterium tuberculosis (M.tb) induces a switch in cell metabolism to active glycolysis.
Through an interdisciplinary approach, combining the fields of clinical microbiology, immunology, metabolism and big data, Dr Llibre research focuses in answering the urgent question of how immune-metabolic responses impact the host’s ability to resolve M.tb infection. This knowledge has the potential to reveal new host immune-metabolic therapeutic targets for TB disease.